The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
AOL13h
What is Compounded Tirzepatide? Here's What You Need to Know
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. If you’re starting a weight loss journey, you might have ...
FDA proposes rule to target asbestos in talc cosmetic products
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
Medpage Today on MSN6d
FDA Approves First Sleep Apnea Drug
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...
healthday on MSN17h
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
HealthDay on MSN4d
FDA Says Shortage of GLP-1 Tirzepatide Is Over
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
Everyday Health3d
FDA Says Shortages of GLP-1 Drugs Mounjaro and Zepbound Are Over
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
The National Law Review6d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
Hold Rating on Inspire Medical Systems Amid FDA Approval of Tirzepatide for OSA
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
TCTMD3d
Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.